【Adimmune Corp.】February 2026 Revenue NT$0.06 Billion (YoY -19.7%)
Adimmune Corporation (4142), a vaccine and biopharmaceutical developer and manufacturer, announced its February 2026 revenue. The company's monthly revenue was NT$0.06 billion, a 19.7% decrease compared to the same period last year. This figure reflects seasonal factors, as the peak flu vaccine shipping season has passed, leading to a traditional off-peak season for revenue.
📋 Article Processing Timeline
- 📰 Published: February 1, 2026 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (1559h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:19 (16h 19m after Collected)
Company Code: 4142
Company Name: Adimmune Corp.
Industry: Biotechnology and Medical Industry
Data Month/Year: 2026-02
Monthly Revenue: NT$5849 Thousand (NT$0.06 Billion)
Year-over-year Change: -19.7%
Company Name: Adimmune Corp.
Industry: Biotechnology and Medical Industry
Data Month/Year: 2026-02
Monthly Revenue: NT$5849 Thousand (NT$0.06 Billion)
Year-over-year Change: -19.7%